Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction involving Mr. R M Bondy, who acquired a beneficial interest in 2 Ordinary shares. These shares were purchased under a Personal Equity Plan on January 11, 2008, at a price of GBP 13.65 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 11, 2008.
- Notification Date: January 16, 2008.
- Individual Involved: Mr. R M Bondy.
- Transaction Type: Acquisition of beneficial interest via Personal Equity Plan.
- Volume and Price: 2 Ordinary shares at GBP 13.65 each.